What innovative solutions is Momentive showcasing at CPHI Milan 2024, and how do these solutions address current challenges in pharmaceutical manufacturing?
Momentive and Safic-Alcan: Driving Innovation in Pharmaceutical Solutions
As a global leader in specialty chemicals and performance materials, Safic-Alcan is committed to driving innovation and delivering high-quality solutions to the pharmaceutical industry. Our extensive portfolio, combined with our deep industry expertise, enables us to provide tailored solutions that meet the stringent demands of pharmaceutical manufacturing. From active pharmaceutical ingredients (APIs) to excipients and advanced drug delivery systems, we partner with world-class suppliers to offer a comprehensive range of products that support the development of safe and effective medicines.
In this exclusive interview, we explore our partnership and the innovative solutions provided by Momentive, as shared by Piermario Ghizzone, Regional Segment Leader Europe PI at Momentive Performance Materials.
At the upcoming CPHI event in Milan 2024, Safic-Alcan is proud to showcase its partnership with Momentive, a global leader in advanced silicones and specialty materials, at booth #6F20. Momentive’s antifoam solutions are engineered to meet the stringent requirements of pharmaceutical manufacturing, ensuring high performance, safety, and regulatory compliance.
Momentive is excited to present a range of pharmaceutical use antifoams, the BC Simethicone series, which are extensively used as Active Pharmaceutical Ingredients (APIs) in gastro-relief drug formulations. These versatile antifoams also find use in the pharmaceutical drug manufacturing process as excipients and processing aids.
Simethicone is widely used in human and veterinary drug formulations. Its primary function is to alleviate gas-related discomfort by breaking down gas bubbles in the gastrointestinal tract. As an excipient, Simethicone improves the delivery and efficacy of Active Pharmaceutical Ingredients formulated into the finished dosage form by providing foam control and lubrication.
Momentive also offers a select range of SAG™ and ESCA™ antifoams extensively used in bio-fermentation applications to prevent foam formation and maximize bioreactor volume, ensuring efficient and productive biopharmaceutical manufacturing.
Momentive is known for its advanced antifoam products. Could you explain the importance of antifoam solutions in pharmaceutical production and how Momentive’s products stand out from the competition?
Gas is trapped as foam in the stomach due to several lifestyle habits and medical conditions. The buildup of foam causes pressure to increase in the stomach. The action of the Simethicone breaks down the bubble walls and allows the smaller bubbles to form into larger ones, which are much easier for the body to expel naturally.
Simethicone antifoams allow drug formulators to create multi-symptom relief products when effectively combined with other active ingredients, such as antacids and digestive enzymes. Our GMP facility produces Simethicone compounds and emulsions that comply with the USP and EP monograph standards. These products are also Kosher and Halal certified, ensuring their suitability for diverse needs and underscoring our commitment to providing high-quality, inclusive solutions.
With a 40-year history of safe use, our BC Simethicone products can streamline the regulatory approval process for new formulations and reduce the time to market. Our dedicated team of experts provides bespoke support and guidance to drug formulators. This legacy and expertise in manufacturing enable Momentive to deliver superior-quality Simethicone products with low volatility and resistance to silica separation.
All aerobic fermentation processes need and use antifoams. Antifoams are used to control foaming in the fermenter in which the fermentation is carried out and to prevent foaming during the separation of the fermentation product. Momentive offers a selective range of high-performance SAG™, ESCA™ antifoam emulsions, and compounds for fermentation applications complying with stringent quality and regulatory requirements. Momentive understands the importance of maintaining a sterile environment in the fermentation processes. That's why Momentive offers sterilizable antifoams that are compatible with downstream separation processes, thereby ensuring the integrity of the fermentation process.
How do you foresee the partnership between Safic-Alcan and Momentive evolving in the coming years, and what future trends do you anticipate in the biopharma production sector?
The global gastrointestinal drugs market is on a growth trajectory. It is estimated to be a $106 Bn market in 2031, growing at a CAGR of 5.4%*. By 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion**, resulting in soaring demand for pharmaceutical API and excipient solutions, aligning with the needs of gastrointestinal drug formulators.
There's a growing interest in biopharmaceutical drug formulations, underscoring the importance of fermentation systems and enablers. As world-class drug innovators invest resources in developing drugs for Immuno-oncology and precision Medicine on bio-based drug platforms, the need for quality and high-performance solutions for their fermentation needs becomes increasingly vital.
Europe will be the focal point of global innovation in driving these trends in the pharmaceutical industry. Momentive is excited to partner with Safic-Alcan to deliver sustainable solutions for regional drug formulators.
